Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01715-20
Keywords
carbonic anhydrase inhibitors; acetazolamide; vancomycin-resistant enterococci (VRE); VRE bloodstream infections; VRE decolonization
Categories
Funding
- National Institutes of Health [R01AI148523]
Ask authors/readers for more resources
Acetazolamide showed promising inhibitory effects against enterococci and outperformed linezolid in VRE mouse models, suggesting it as a potential treatment option for VRE infections.
Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two in vivo VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available